Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fausto Petrelli

Showing results (281-290 of 304) with videos related to

Pageof 31
Sort By:
The Oncologist|June 8, 2021
Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority StudyLuigi Celio, Diego Cortinovis, Alessio Aligi Cogoni, et al.
BMC Cancer|August 23, 2022
Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 studyLuigi Celio, Diego Cortinovis, Alessio Aligi Cogoni, et al.
JAMA Oncology|March 3, 2022
Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical TrialXavier Pivot, M A Georgievich, Volodymyr Shamrai, et al.
JAMA Oncology|February 14, 2020
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical TrialFausto Petrelli, Roberto Labianca, Alberto Zaniboni, et al.
International Journal of Cancer|June 9, 2022
Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trialAlessandra Raimondi, Giovanni Randon, Michele Prisciandaro, et al.
Haematologica|September 28, 2019
Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancerCinzia Giaccherini, Marina Marchetti, Giovanna Masci, et al.
Expert Opinion on Biological Therapy|November 21, 2014
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysisNicola Silvestris, Mario Scartozzi, Giusi Graziano, et al.
Frontiers in Oncology|December 7, 2020
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone MetastasesMarta Laganà, Cristina Gurizzan, Elisa Roca, et al.
The Lancet. Oncology|May 17, 2014
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trialVanesa Gregorc, Silvia Novello, Chiara Lazzari, et al.
Journal of Thrombosis and Haemostasis : JTH|March 8, 2025
Activated factor XI-antithrombin and thrombin-antithrombin complexes in the prediction of venous thromboembolism and mortality in patients with non-small-cell lung cancerPatricia Gomez-Rosas, Magdolna Nagy, Henry M H Spronk, et al.
Pageof 31

Showing results (281-290 of 304) with videos related to

Sort By:
Pageof 31
The Oncologist|June 8, 2021
Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority StudyLuigi Celio, Diego Cortinovis, Alessio Aligi Cogoni, et al.
BMC Cancer|August 23, 2022
Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 studyLuigi Celio, Diego Cortinovis, Alessio Aligi Cogoni, et al.
JAMA Oncology|March 3, 2022
Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical TrialXavier Pivot, M A Georgievich, Volodymyr Shamrai, et al.
JAMA Oncology|February 14, 2020
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical TrialFausto Petrelli, Roberto Labianca, Alberto Zaniboni, et al.
International Journal of Cancer|June 9, 2022
Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trialAlessandra Raimondi, Giovanni Randon, Michele Prisciandaro, et al.
Haematologica|September 28, 2019
Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancerCinzia Giaccherini, Marina Marchetti, Giovanna Masci, et al.
Expert Opinion on Biological Therapy|November 21, 2014
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysisNicola Silvestris, Mario Scartozzi, Giusi Graziano, et al.
Frontiers in Oncology|December 7, 2020
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone MetastasesMarta Laganà, Cristina Gurizzan, Elisa Roca, et al.
The Lancet. Oncology|May 17, 2014
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trialVanesa Gregorc, Silvia Novello, Chiara Lazzari, et al.
Journal of Thrombosis and Haemostasis : JTH|March 8, 2025
Activated factor XI-antithrombin and thrombin-antithrombin complexes in the prediction of venous thromboembolism and mortality in patients with non-small-cell lung cancerPatricia Gomez-Rosas, Magdolna Nagy, Henry M H Spronk, et al.
Pageof 31